SAN DIEGO and
TORONTO, Oct. 30, 2014 /PRNewswire/ - Aptose Biosciences
Inc. (Aptose) (NASDAQ: APTO; TSX:APS), a clinical-stage
company developing targeted agents and molecular diagnostics to
treat the underlying mechanisms of cancer, today announced it
intends to release financial results for the four month interim
period ended September 30, 2014, on
Tuesday, November 4, 2014 after the
close of the market. The company intends to host a conference
call on the same day at 5:00 p.m. ET
to discuss the financial results.
Effective July 15,
2014, Aptose changed its fiscal year end from May 31 to December 31. As a result of that
change, the current interim period is for the four months ended
September 30, 2014.
Participants can access the conference call by
dialing 1-888-231-8191 (North American toll free number) or
647-427-7450 (local). The conference call will be available
via a live webcast at
http://www.newswire.ca/en/webcast/detail/1435873/1595769, and will
also be available through a link on the Investor Relations section
of Aptose's website at http://www.aptose.com/events/. Please
log on to the webcast at least 10 minutes prior to the start of the
call to ensure time for any software downloads that may be
required. An archived version of the webcast will be
available on the company's website for 30 days. An
audio replay of the webcast will be available approximately two
hours after the conclusion of the call for 30 days by dialing
1-855-859-2056, using the passcode 28685150.
The press release, financial statements and the
management's discussion and analysis for the four month interim
period ended September 30, 2014 will
be available on the Company's website at www.aptose.com.
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to discovering and developing
personalized therapies addressing unmet medical needs in oncology.
Aptose is advancing new therapeutics focused on novel cellular
targets on the leading edge of cancer research coupled with
companion diagnostics to identify the optimal patient population
for our products. The company's small molecule cancer therapeutics
pipeline includes products designed to provide additive or
synergistic efficacy with existing anti-cancer therapies and
regimens without overlapping toxicities. Aptose Biosciences Inc. is
listed on the TSX under the symbol APS and is on NASDAQ under the
symbol APTO.
This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws.
Such statements include, but are not limited to, statements
relating to Aptose's plans, objectives, expectations and intentions
and other statements including words such as "continue", "expect",
"intend", "will", "should", "would", "may", and other similar
expressions. Such statements reflect our current views with respect
to future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such expressed or implied factors
include, among others: changes in our stock price; our ability to
meet listing requirements; our ability to obtain the capital
required for research and operations; the inherent risks in early
stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the
progress of our clinical trials; our ability to find and enter into
agreements with potential partners; our ability to attract and
retain key personnel; changing market conditions; stock market
volatility; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties
materialize, or should the assumptions set out in the section
entitled "Risk Factors" in our filings with Canadian securities
regulators and the United States Securities and Exchange Commission
underlying those forward-looking statements prove incorrect, actual
results may vary materially from those described herein. These
forward-looking statements are made as of the date of this press
release and we do not intend, and do not assume any obligation, to
update these forward-looking statements, except as required by law.
We cannot assure you that such statements will prove to be accurate
as actual results and future events could differ materially from
those anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
SOURCE Aptose Biosciences Inc.
PDF available at:
http://stream1.newswire.ca/media/2014/10/30/20141030_C9237_DOC_EN_43143.pdf
